Merck 2010 Annual Report Download - page 169
Download and view the complete annual report
Please find page 169 of the 2010 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159 -
160 -
161 -
162 -
163 -
164 -
165 -
166 -
167 -
168 -
169 -
170 -
171 -
172 -
173 -
174 -
175 -
176 -
177 -
178 -
179 -
180
-
181
-
182
-
183
-
184
-
185
-
186
-
187
-
188
-
189
-
190
-
191
-
192
-
193
-
194
-
195
-
196
-
197
-
198
-
199
-
200
-
201
-
202
-
203
-
204
-
205
-
206
-
207
-
208
-
209
-
210
-
211
-
212
-
213
-
214
-
215
-
216
-
217
-
218
-
219
-
220
-
221
-
222
-
223
 |
 |
Other receivables and other assets include an amount of EUR 269.3 million from the sale of Théramex
(see “Scope of consolidation – Divestment of Théramex”) and mainly prepayments as well as interest
deferrals. In 2010, a separate line item was introduced for non-income-related taxes (mainly value
added tax). The previous year’s figures have been adjusted.
Other assets comprise the following:
Other receivables from third parties past due are as follows:
EUR million
Dec. 31,
2010
Dec. 31,
2009
Neither impaired nor past due 345.0 68.7
Past due, but not impaired
up to 3 months 8.4 7.8
up to 6 months 4.8 1.3
up to 12 months 0.6 0.2
over 1 year 2.0 0.6
Impaired 26.9 –
Book value 387.7 78.6
A settlement payment was made to the U.S. Department of Justice in 2010 in connection with the
litigation of our former subsidiary Dey, Inc., USA, which we sold to Mylan (see Note [32]). Insofar as
this payment is tax-deductible, Merck is entitled to claim reimbursement from Mylan in the amount
of the tax credit. The exact amount cannot be definitively determined at this point in time. Merck
wrote down this claim by EUR 52.6 million to a residual value of EUR 26.9 million. The expense
resulting from this write-down is recorded under “Exceptional items”. Write-ups of other receivables
from third parties were not necessary in either 2010 or 2009. With regard to other receivables that
are neither impaired nor delayed, as of the reporting date there are no indications that the debtors
will not meet their payment obligations.
EUR million current non-current
Dec. 31,
2010 current non-current
Dec. 31,
2009
Receivables from third parties 385.6 2.1 387.7 76.5 2.1 78.6
Receivables from related parties 17.0 – 17.0 14.9 – 14.9
Receivables from affiliates 2.4 – 2.4 – – –
Other receivables 405.0 2.1 407.1 91.4 2.1 93.5
Receivables from non-income related taxes 72.8 36.0 108.8 83.3 54.5 137.8
Prepaid expenses 48.2 2.7 50.9 48.9 3.7 52.6
Refund claims on plan assets 18.8 – 18.8 15.2 – 15.2
Derivative assets (operational) 2.2 0.4 2.6 29.5 28.6 58.1
Other assets 17.7 11.7 29.4 7.3 10.6 17.9
564.7 52.9 617.6 275.6 99.5 375.1
Company 165Management Report Corporate governance Consolidated Financial Statements
Notes
More information